0001493152-23-024286.txt : 20230712 0001493152-23-024286.hdr.sgml : 20230712 20230712084457 ACCESSION NUMBER: 0001493152-23-024286 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230707 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230712 DATE AS OF CHANGE: 20230712 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biofrontera Inc. CENTRAL INDEX KEY: 0001858685 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473765675 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40943 FILM NUMBER: 231083317 BUSINESS ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 781-245-1325 MAIL ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 form8-k.htm
0001858685 false 0001858685 2023-07-07 2023-07-07 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2023-07-07 2023-07-07 0001858685 BFRI:PreferredStockPurchaseRightsMember 2023-07-07 2023-07-07 0001858685 BFRI:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember 2023-07-07 2023-07-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 7, 2023

 

Biofrontera Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40943   47-3765675
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

120 Presidential Way, Suite 330

Woburn, Massachusetts

   01801
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 245-1325

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class  

Trading Symbol(s)

  

Name of each exchange on which registered

Common stock, par value $0.001 per share   BFRI   The Nasdaq Stock Market LLC
Preferred Stock Purchase Rights       The Nasdaq Stock Market LLC
Warrants to purchase common stock   BFRIW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On July 7, 2023, the board of directors (the “Board”) of Biofrontera Inc. (the “Company”) appointed Heikki Lanckriet to the Board. Mr. Lanckriet will serve as a Class I Director to hold office for a term expiring at the annual meeting of the Company’s stockholders for fiscal year 2025. Mr. Lanckriet’s term as director began upon his appointment at the July 7, 2023 meeting. Mr. Lanckriet does not currently serve on any committees of the Board.

 

Mr. Lanckriet was appointed to the Board upon the nomination of Biofrontera AG, a significant stockholder of the Company, pursuant to a settlement agreement (the “Settlement Agreement”), dated as of April 11, 2023, between the Company, each member of its Board of Directors at that time and Biofrontera AG which was previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on April 17, 2023. Other than the Settlement Agreement, there is no arrangement or understanding between Mr. Lanckriet and any other person pursuant to which he was appointed as director.

 

Mr. Lanckriet has not been involved in any related party transaction within the meaning of Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended and required to be disclosed herein.

 

Mr. Lanckriet’s compensation will be as provided under the Company’s non-employee director compensation policy as disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 13, 2023. Mr. Lanckriet will receive a $40,250 annual retainer for his service as a director, which will be pro-rated for the remainder of the calendar year 2023. If he is appointed to one or more Board committees, he would receive an additional annual retainer. Mr. Lanckriet will also receive an annual award of common stock of the Company.

 

Item 7.01 Regulation FD Disclosure

 

On July 12, 2023 the Company issued a press release announcing the appointment described in Item 5.02 of this Current Report on Form 8-K (the “Form 8-K”). The full text of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

 

The information contained in Item 7.01 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

99.1 Press Release dated July 12, 2023
104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

July 12, 2023

(Date)

Biofrontera Inc.

(Registrant)

   
 

/s/ E. Fred Leffler III

  E. Fred Leffler III
  Chief Financial Officer

 

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

 

WOBURN, Mass. (July 12, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies.

 

Dr. Lanckriet was nominated to Biofrontera Inc.’s Board of Directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 17, 2023. Dr. Lanckriet currently serves as a member of Biofrontera AG’s Supervisory Board.

 

Dr. Lanckriet currently serves as Chief Executive Officer and Chief Scientific Officer of 4basebio PLC, UK, a publicly traded company that engages in the research, development, manufacturing and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions which was spun out of Expedeon AG in 2021. In 2020 Heikki led the sale of Expedeon’s proteomics and immunology business to Abcam PLC. Earlier, Dr. Lanckriet was Founder and Chief Scientific Officer of Novexin, later transitioning to Chief Operating Officer. Dr. Lanckriet also held roles as Chief Executive Officer and Chief Scientific Officer at 2invest AG and Sygnis AG.

 

“Heikki’s ambition and keen understanding of translating science to commercial success will be a valuable addition to our Board of Directors. We look forward to his contributions and resources having served as both a life sciences executive and investor,” commented Hermann Luebbert, Chairman and Chief Executive Officer of Biofrontera Inc. “We enjoy a constructive relationship with Biofrontera AG and welcome their participation in our company’s governance and strategic positioning, as determined by the settlement agreement. Of particular note, Biofrontera AG is leading the clinical trials that we expect will enhance the use of Ameluz® in current indications and expand its label to include new, large market opportunities.”

 

“I am delighted to join the Board of Directors of Biofrontera, which is redefining the landscape for the treatment of actinic keratosis and other dermatological conditions in the US. My passion is in empowering teams to seize advancements in healthcare to improve the quality of patient care, and I recognize Biofrontera’s commercial potential with Ameluz, photodynamic therapy and more,” said Dr. Lanckriet.

 

Dr. Lanckriet holds a Ph.D. in Chemical Engineering from the University of Cambridge in the U.K. and a M.Eng. in Chemical Engineering from the University of Ghent in Belgium. He has authored several scientific papers that have been published in peer-reviewed medical and scientific journals, and is a named inventor on a multitude of patents.

 

About Biofrontera Inc.

 

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of products for the treatment of dermatologic conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.

 

 
 

 

Forward-Looking Statements

 

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company’s relationship with Biofrontera AG, the impact of current clinical trials of Ameluz®, the potential expansion of the label for Ameluz® and increased market opportunities for Ameluz®. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of any extraordinary external events; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; the Company’s ability to comply with public company requirements; the Company’s ability to regain compliance with Nasdaq continued listing standards, the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

 

Contact:

 

LHA Investor Relations

Tirth T. Patel

212-201-6614

tpatel@lhai.com

 

# # #

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 bfri-20230707.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 bfri-20230707_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 bfri-20230707_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common stock, par value $0.001 per share Preferred Stock Purchase Rights Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 7 bfri-20230707_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jul. 07, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 07, 2023
Entity File Number 001-40943
Entity Registrant Name Biofrontera Inc.
Entity Central Index Key 0001858685
Entity Tax Identification Number 47-3765675
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 120 Presidential Way
Entity Address, Address Line Two Suite 330
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code (781)
Local Phone Number 245-1325
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Entity Information, Former Legal or Registered Name Not Applicable
Common stock, par value $0.001 per share  
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol BFRI
Security Exchange Name NASDAQ
Preferred Stock Purchase Rights  
Title of 12(b) Security Preferred Stock Purchase Rights
Security Exchange Name NASDAQ
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share  
Title of 12(b) Security Warrants to purchase common stock
Trading Symbol BFRIW
Security Exchange Name NASDAQ
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001858685 2023-07-07 2023-07-07 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2023-07-07 2023-07-07 0001858685 BFRI:PreferredStockPurchaseRightsMember 2023-07-07 2023-07-07 0001858685 BFRI:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember 2023-07-07 2023-07-07 iso4217:USD shares iso4217:USD shares 0001858685 false 8-K 2023-07-07 Biofrontera Inc. DE 001-40943 47-3765675 120 Presidential Way Suite 330 Woburn MA 01801 (781) 245-1325 Not Applicable false false false false Common stock, par value $0.001 per share BFRI NASDAQ Preferred Stock Purchase Rights NASDAQ Warrants to purchase common stock BFRIW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 4 25 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biofrontera.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-60546-SecurityExchangeName-TradingSymbol, NoTradingSymbolFlag-Dependency] In submission type 8-K, SecurityExchangeName should have a value if one of TradingSymbol, NoTradingSymbolFlag has a value in context From2023-07-072023-07-07_custom_PreferredStockPurchaseRightsMember. form8-k.htm 257 form8-k.htm bfri-20230707.xsd bfri-20230707_def.xml bfri-20230707_lab.xml bfri-20230707_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "bfri-20230707_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "bfri-20230707_lab.xml" ] }, "presentationLink": { "local": [ "bfri-20230707_pre.xml" ] }, "schema": { "local": [ "bfri-20230707.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 67, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 3, "memberStandard": 0, "nsprefix": "BFRI", "nsuri": "http://biofrontera.com/20230707", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-07-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://biofrontera.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-07-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "BFRI_CommonStockParValue0.001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.001 per share" } } }, "localname": "CommonStockParValue0.001PerShareMember", "nsuri": "http://biofrontera.com/20230707", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "BFRI_PreferredStockPurchaseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Purchase Rights" } } }, "localname": "PreferredStockPurchaseRightsMember", "nsuri": "http://biofrontera.com/20230707", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "BFRI_WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share" } } }, "localname": "WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember", "nsuri": "http://biofrontera.com/20230707", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001493152-23-024286-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-024286-xbrl.zip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end